Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy.
Carnitine and acylcarnitines were measured in plasma and tissues of control turkeys, turkeys with an inbred spontaneous cardiomyopathy, and turkeys with furazolidone-induced cardiomyopathy. Heart failure was evident in both types of cardiomyopathy from decreased systemic blood pressure and cardiac dilatation compared to controls. Plasma free carnitine, short-chain acylcarnitine, and long-chain acylcarnitine were significantly elevated by 76 to 614% (p less than 0.01) in the two cardiomyopathy models compared to control. The highest carnitine levels were found in the most hypotensive turkeys. Liver free carnitine and short-chain acylcarnitine levels were also elevated by 45 to 537% (p less than 0.05) in both types of cardiomyopathy. Free carnitine was elevated by 126% in left ventricle and by 54% in skeletal muscle of the furazolidone-treated turkeys (p less than 0.05). We speculate that hepatic synthesis of carnitine may be increased in response to hypotension and progressive cardiac dysfunction in cardiomyopathic turkeys. Such an increase may be useful to promote beta-oxidation of fatty acids as a cardiac energy source.
D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced / Q000378:metabolism* / Q000662:veterinary; D002331:Carnitine / Q000097:blood / Q000378:metabolism*; D005664:Furazolidone / Q000633:toxicity; D006333:Heart Failure / Q000378:metabolism*; D006439:Hemodynamics; D008099:Liver / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D011201:Poultry Diseases / Q000139:chemically induced / Q000378:metabolism; D014018:Tissue Distribution; D014422:Turkeys
D005664:Furazolidone; D002331:Carnitine